Below are brief descriptions of key figures connected with Oncimmune Ltd.
The UK board of Oncimmune is:
|Geoffrey Hamilton–Fairley||– CEO|
|Timothy Bunting||– Non Executive Chairman|
|Dan Calvo||– Non Executive Director|
|Peter Morgan||– Non Executive Director|
|Dr Alan Raymond||– Non Executive Director|
|Soren Thestrup-Nielsen, MD||– Non Executive Director|
|Richard Sharp||– Non Executive Director|
|Bob Page||– Chief Financial Officer|
Additional key personnel within Oncimmune are:
|Andrea Murray||– Chief Operational Scientist|
Please click here for information on the Scientific Advisory Board of Oncimmune.
Geoffrey Hamilton–Fairley, CEO, has an entrepreneurial career that started in 1982 when Geoffrey founded a number of companies in the media sector backed by The Abingdon Management Company Limited (Abingdon). In 1988 he joined the board of Abingdon as CEO and subsequently became sole owner having acquired the company from its institutional shareholders. Abingdon had a number of quoted and unquoted investments – perhaps the most noteworthy being Fortronic which developed the first magnetic strip plastic card swipe technology. In 1998 he launched Premium TV (PTV) securing a contractual joint venture with Eurosport to create “British Eurosport”. Later that year PTV was acquired by NTL (now Virgin Media). As CEO of PTV Geoffrey instigated and oversaw the highly complex development of the largest integrated broadband and internet sports broadcasting platform in the world (it still remain this today some 8 years later). Over the past ten years Geoffrey has increasingly focused his time and energies on the health sector, and has dedicated almost all of his time in the past 5 years to the development of Oncimmune Ltd, serving as its Executive Chairman. His personal commitment to cancer detection can be traced to his father, the first medical oncologist in the United Kingdom.
Tim Bunting, Non Executive Chairman, joined Balderton as a General Partner in 2007. He was previously a partner of Goldman Sachs where he spent 18 years. At Goldman, Tim held various roles including Global Head of Equity Capital Markets (2002 to 2005) and Vice-Chairman of Goldman Sachs International (2005 to 2006). Tim started to work with Balderton and its portfolio of companies in 2005. In 2006 Tim spent a period as non-executive chairman of Betfair. Tim is also a Governor of Wellington College and the Wellington Academy; a Trustee of the Rainbow Trust Children's Charity and the Paul Hamlyn Foundation. Tim is a graduate of the University of Cambridge.
Dan Calvo served as President and CEO of Oncimmune USA LLC since June, 2009 until the acquisition of the US laboratory operations in October, 2013. He currently is the President and CEO of Gyros, AB, a global immunoassay instrument company. Prior to joining Oncimmune, Dan was the CEO of two successful companies, Cellomics and Assay Designs, both of which were acquired, by Fisher Scientific and Enzo Biochem respectively. He had a 20 year progressive career with DuPont, and then served as Commercial SVP of NEN Life Sciences, a spinout company of DuPont, which was sold to PerkinElmer. Dan also served as global commercial VP there until joining Cellomics as CEO in 2003. He also serves as Chairman of the Board of Optra Systems, an India-based healthcare IT company.
Peter Morgan joined the board of Oncimmune as an independent director in 2005. He has a degree from Nottingham University and an MBA from London Business School. After an early career in the pharmaceutical industry, Peter founded business services group Beaufort Group plc which he IPO’d in 1996. He has advised half of the global top 10 pharmaceutical companies as well as a number of leading global medical diagnostics companies. Peter is the Senior Independent Director at Oncimmune in which role he is in frequent dialogue with Geoffrey Hamilton-Fairley in his role as CEO and Chairman. Peter also sits on the Oncimmune Audit Committee and Science Committee.
Dr. Alan Raymond has 30 years of international marketing and general management experience within the pharmaceutical and biomedical industry. Alan has raised seedcorn funding and been an Executive Director of early stage life science companies including; Pro-Cure Therapeutics, a University of York drug discovery spin-off company, and Critical Pharmaceuticals, a University of Nottingham drug delivery spin off company. Alan is currently the Executive Sales and Marketing Director and a shareholder of the PE backed contract development and manufacturer, Aesica Pharmaceuticals Ltd. During his career Alan progressed through senior executive and marketing roles in Banner Pharmacaps, RP Scherer, Reckitt and Colman, Eli Lilly, and MSD within the UK, Netherlands and Australia. Prior to his industrial career Alan was postdoctoral researcher in the Cardiothoracic Research Institute (London) and his Ph.D (St. Andrews) is in invertebrate neurobiology.
Dr. Soren Thestrup-Nielsen joined Danaher Corporation in 2007 as VP of Business Development, and leads Danaher’s corporate business development and M&A activities within medical technology and diagnostics. In this role, he was instrumental in Danaher’s acquisition of Beckman Coulter in 2011. After receiving his medical degree in 1991, Dr. Thestrup-Nielsen trained as general and vascular surgeon in Denmark and France, after which he joined Boston Scientific Corporation in 1997 as Director of Healthcare Strategies. In 1999, Dr. Thestrup-Nielsen founded a strategic advisory firm in Boston, MA offering strategic and financial services to a significant number of United States and Europe venture-backed medical device companies and venture capital firms in the area of medical technology. Dr. Thestrup-Nielsen also specialized in advising private equity firms and corporations on investment target suitability, M&A target evaluations, and market analysis. During the same period of time, Dr. Thestrup-Nielsen was co-founder to three start-up companies and sat on the board of several other high technology start-up companies. Dr. Thestrup-Nielsen holds an M.D. degree from the University of Copenhagen, School of Medicine and an MBA from IMD (Switzerland).
Richard Sharp graduated from Oxford University and began his professional career in 1978 working for JPMorgan in UK Banking, then in Investment Banking and Derivatives. In 1985, Richard joined Goldman Sachs in London and variously served as Head of Capital Markets, Head of UK investment Banking and Head of European Private Equity and Mezzanine Investing. Richard left Goldman in 2007 to found and run DII Capital LLP. In the summer of 2013, Richard became an External Appointee of the HM Treasury on the Financial Policy Committee of the Bank of England which is responsible for Macro-Prudential Supervision in the UK.
Andrea Murray studied Applied Biology at Nottingham Trent University before reading for a PhD in Pharmaceutical Sciences at the University of Nottingham. The focus of Dr Murray’s PhD studies, which were performed under the supervision of Professor Mike Price at the Cancer Research Laboratories, was the development of monoclonal antibodies for diagnosis of cancer. She later worked on the development of peptide mimetics for purification of monoclonal antibodies and antibody fragments then spent three years developing radioimmunoconjugates for diagnosis and treatment of bladder cancer. During this postdoctoral research position Andrea was awarded a travel fellowship by the European Association for Cancer Research which allowed her to spend a period of training at the Paul Scherrer Institute in Switzerland where she worked on the development of techniques for conjugating rhenium-188 to biological molecules such as antibodies. Andrea has also worked as Senior Research Fellow on a DEFRA funded project concerned with the biological effects of organophosphate pesticides on brain tissue before joining Oncimmune Ltd as Senior Director of Assay Development. Dr Murray has published over 40 papers in peer reviewed journals and has written several book chapters and invited reviews. She has presented her work at numerous national and international conferences. Dr Murray joined Oncimmune in 2004 as one of the company’s first employees. She has been involved with the EarlyCDT-Lung test through all of its stages of development and validation and has provided critical technical leadership since.